Quantcast

Latest Aethlon Medical Stories

2014-09-02 12:28:32

SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has received independent internal review board (IRB) approval to initiate human clinical studies of Hemopurifier® therapy at DaVita MedCenter Dialysis located in Houston, Texas. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b...

2014-08-06 12:28:09

SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b The current ebola outbreak in West Africa demonstrates the urgent need for therapeutic strategies to defend against emerging pandemic threats. It also highlights why the Department of Health and Human Services (HHS) has shifted the focus of government biodefense and...

2014-06-25 12:29:13

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19(th), is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at...

2014-06-17 12:30:02

SAN DIEGO, June 17, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at The Wall Street Analyst Forum 25(th) Annual Institutional Investor Conference on Thursday, June 19(th), at 12:05 PM EDT. Mr. Joyce's presentation will include an...

2014-06-10 08:30:28

POINT ROBERTS, Wash. and NEW YORK, June 10, 2014 /PRNewswire/ -- Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a Q&A interview with Mr. James A. Joyce ,Chairman and CEO of Aethlon Medical, Inc. (OTCBB: AEMD). Mr. Joyce shares insight into the emerging Immuno-Oncology market and the opportunity it represents. Q: Investorideas.com How did Aethlon Medical become involved in cancer research? A: James A. Joyce,...

2014-05-20 08:33:24

SAN DIEGO, May 20, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into a definitive agreement with DaVita Clinical Research( )(DCR) to provide clinical management services to support the forthcoming feasibility study of the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class therapeutic...

2014-04-22 08:33:24

SAN DIEGO, April 22, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b When we initiated our first exosome research program, the medical community generally viewed these particles as nothing more than cellular debris with no biological function. In contrast, we believed that exosomes, also known as microvesicles or extracellular vesicles,...

2014-04-09 08:30:08

SAN DIEGO, April 9, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b In the coming months, we plan to initiate the first FDA approved study of Hemopurifier® therapy in the United States. Historically, U.S. clinical progression of extracorporeal devices directed toward a single disease indication has been a proven model for value...

2014-03-05 08:29:37

Discoveries Could Have Implications in the Diagnosis, Monitoring and Treatment of Alzheimer's Disease, Chronic Traumatic Encephalopathy and Traumatic Brain Injury SAN DIEGO, March 5, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications...

2014-02-26 08:29:00

SAN DIEGO, Feb. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in principle with DaVita Clinical Research® (DCR) to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class therapeutic...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related